Cognition Therapeutics, Inc. (CGTX)

Market Cap	115.27M +484.1%
Revenue (ttm)	n/a
Net Income	-19.58M
EPS	-0.25
Shares Out	89.35M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,149,545
Open	1.330
Previous Close	1.360
Day's Range	1.220 - 1.330
52-Week Range	0.250 - 3.830
Beta	1.75
Analysts	Strong Buy
Price Target	3.50 (+171.32%)
Earnings Date	May 7, 2026

About CGTX

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer’s disease and Mild Cognitive Impairment, as well as geographic atr...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 8, 2021
• Employees: 14
• Stock Exchange: NASDAQ
• Ticker Symbol: CGTX
• Website: https://www.cogrx.com

Analyst Summary

According to 4 analysts, the average rating for CGTX stock is "Strong Buy." The 12-month stock price target is $3.5, which is an increase of 171.32% from the latest price.

Price Target

$3.5

(171.32% upside)

Analyst Consensus: Strong Buy